Feature | September 13, 2013| Dave Fornell

Vascular Closure Devices Aid Closure of Large Access Sites

Off-label use of closure devices speeds hemostasis following TEVAR, TAVR and pVAD use

There is no shortage of debate among interventional cardiologists over whether vascular closure devices should be used for standard cath lab procedures. However, some say these devices have a definite niche in areas where they were not originally intended but have found frequent off-label use because of their utility. 

The larger sizes of devices used for transcatheter endovascular aortic repair (TEVAR) and transcatheter aortic valve replacement (TAVR) requires a much larger arteriotomy site than standard percutaneous coronary interventions (PCI). However, these larger holes also make it more difficult to achieve hemostasis using manual compression alone. 

Some of these devices are as large as 24 French, and anything larger requires a surgical cut-down, said Chris Malaisrie, M.D., assistant professor of surgery, division of cardiac surgery, Northwestern University Memorial Hospital, Chicago. “You can’t just hold pressure on a hole that size,” Malaisrie explained. “I use the preclose technique for large bore access for TEVAR and TAVI. I currently use Abbott Prostar or Abbott Perclose Proglide off-label. I prefer the ProGlide, even though you need two of them to close.”

The Abbott Perclose ProGlide suture-mediated closure system provides a suture for vascular closure of 5 – 21 French femoral artery access sites. The vendor says for sheath sizes greater than 8 French, at least two devices and the pre-close technique are required. The system helps reduce time to hemostasis, ambulation and discharge. 

Another off-label application of these devices has been found when using percutaneous ventricular assist devices (pVADs), such as the Abiomed Impella or the CardiacAssist TandemHeart systems. The TandemHeart system uses cannula sizes up to 17 French. 

“We primarily use two ProGlides for Impella 13 French closure using an off-label pre close technique,” said Mladen Vidovich, M.D., FACC, FSCAI, chief, section of cardiology, Jesse Brown VA Medical Center, and associate professor of medicine, University of Illinois, Chicago. 

He said cath labs at both Jesse Brown VA and UIC used closure devices on a regular basis for femoral access PCI in the past to speed patient ambulation and cut nursing time. However, he said both facilities have drastically reduced the need for these devices. 

“Due to our high radial access volume, our closure device use has dwindled, but for the rare groin I’ll use Proglide,” Vidovich said.   

Related Content

medtronic corevalve, tavr
News | February 03, 2016 | Dave Fornell
Medtronic announced Feb. 3 that the U.S.
Cook Medical Zenith Alpha Thoracic Endovascular Graft, first U.S. patient, Cleveland Clinic
News | Stent Grafts| January 28, 2016
In November, following the U.S. Food and Drug Administration approval of Cook Medical’s Zenith Alpha Thoracic...
Sponsored Content | Case Study | Cardiovascular Ultrasound| January 21, 2016
This case study is from the Cardiac Imaging Department, Hospital Clinic, Barcelona, Spain.
Vivasure Medical, PerQSeal, vascular closure device, CE Mark
News | Vascular Closure Devices| January 18, 2016
Vivasure Medical announced Conformité Européenne (CE) Mark approval of the world’s first fully bioabsorbable...
AVR, aortic valve replacement, middle-aged patients, University of Sydney study, metal, tissue
News | Heart Valve Repair| January 15, 2016
Patients between the ages of 40 and 70 who undergo aortic valve replacement (AVR) may fare better with tissue-based...
Sapien III, Sapien 3, PARTNER III

The Edwards Sapien 3 valve uses a skirt at its base to prevent paravalvular leak. This is the newest version of the Sapien and will be used in the upcoming PARTNER III Trial.

Feature | Heart Valve Repair| January 15, 2016 | Dave Fornell
January 15, 2016 — The U.S.
heart valve formation, newborns, congenital heart defects, Cornell study
News | Congenital Heart| January 14, 2016
January 14, 2016 — Cornell biomedical engineers have discovered natural triggers that could reduce the chance of life
News | Ventricular Assist Devices (VAD)| January 08, 2016
XENiOS announced that its i-COR Synchronized Cardiac Assist system protects left ventricular (LV) function compared to...
News | Hemostasis Management| January 06, 2016
The Medicines Company announced Dec. 18 it has entered into a purchase agreement pursuant to which certain subsidiaries...
Feature | Ventricular Assist Devices (VAD)| December 28, 2015
December 28, 2015 — National Cheng Kung University (NCKU) in Taiwan and Duke University School of Medicine are collab
Overlay Init